Immunovant, Inc. (IMVT) stock analysis
In our weekly check, Immunovant, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 10.
About Immunovant, Inc.
Immunovant, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as IMVT.
What our checks show for IMVT
Red flags
- The net margin fell by 7174 points over 5 years, to -7174%: the company keeps less of each sale as profit.
- Weak EPS forecast
- Weak EPS growth
- The company is losing money.
- Free cash flow is negative: the business spends more cash than it brings in.
- The price swings a lot: 52.7% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 94% from a peak. Would you have held through that?
- The share count grew by 32.1% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- The stock is still below its previous peak.
Strengths
- Debt is low: 0x equity.
- The company has no debt, so interest is not a risk.
- The gross margin is 100% and has risen by 100 points: pricing power is holding.
- Analysts expect revenue to grow about 398% a year over the next years.
- Analysts expect the net margin to improve by 7090 points from today's -7174%.
Next earnings report: 2027-02-05
Similar companies
TXG · ORKA · KOD · TWST · ARWR · AXSM
Questions
What grade does Immunovant, Inc. (IMVT) have?
In our weekly check, Immunovant, Inc. is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of IMVT stock?
This week's biggest flags for Immunovant, Inc.: Margins falling, Weak EPS forecast, Weak EPS growth. In total 12 of 21 checks show a warning or a red flag.
What does Immunovant, Inc. do?
Immunovant, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as IMVT.
When does Immunovant, Inc. report earnings next?
The next earnings report is expected on 2027-02-05. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis